Literature DB >> 10209521

Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon.

M Molteni1, S Della Bella, B Mascagni, S Bazzi, C Zulian, S Compasso, M Lessi, R Scorza.   

Abstract

The aim of the present study was to analyse the in vitro proliferation and cytokine production by alloantigen-stimulated peripheral blood mononuclear cells (PBMC) obtained from patients affected by systemic sclerosis (SSc) and patients with Raynaud's phenomenon (RP). In SSc patients the proliferation of PBMC stimulated in vitro with alloantigens was significantly increased compared with healthy subjects, while no differences were observed for RP patients. Lymphocytes from SSc patients also produced larger amounts of IFN-gamma compared with healthy controls. However, patients with clinically active disease had lower IFN-gamma levels than those found in clinically stable patients. Patients affected by RP showed significantly higher levels of IFN-gamma than healthy subjects. Analysis at the clonal level of the lymphocyte subsets involved in alloantigen stimulation in one patient affected by active SSc, and one subject with RP confirmed the results obtained using PBMC. In particular, in the RP patient but not in the SSc patient, we observed a population of CD4+ T cells which proliferated to alloantigens in vitro and produced high levels of IFN-gamma. We suggest that T lymphocytes producing high levels of IFN-gamma might play a protective role in RP patients and in established scleroderma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10209521      PMCID: PMC1905213          DOI: 10.1046/j.1365-2249.1999.00842.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

Review 1.  On scleroderma. Mast cells, endothelial cells, and fibroblasts.

Authors:  H N Claman
Journal:  JAMA       Date:  1989-09-01       Impact factor: 56.272

2.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

3.  Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Association with a coordinate decrease in types I and III procollagen messenger RNA levels.

Authors:  J Rosenbloom; G Feldman; B Freundlich; S A Jimenez
Journal:  Arthritis Rheum       Date:  1986-07

4.  CD11/CD18-independent neutrophil adherence to inducible endothelial-leucocyte adhesion molecules (E-LAM) in vitro.

Authors:  A Dobrina; B R Schwartz; T M Carlos; H D Ochs; P G Beatty; J M Harlan
Journal:  Immunology       Date:  1989-08       Impact factor: 7.397

5.  Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration.

Authors:  M B Kahaleh; E C LeRoy
Journal:  Ann Intern Med       Date:  1989-03-15       Impact factor: 25.391

6.  Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine.

Authors:  S Della Bella; M Molteni; B Mascagni; C Zulian; S Compasso; R Scorza
Journal:  Clin Exp Rheumatol       Date:  1997 Mar-Apr       Impact factor: 4.473

7.  The SL/Ki system in connective tissue diseases: incidence and clinical associations.

Authors:  P Riboldi; R Asero; L Origgi; S Crespi
Journal:  Clin Exp Rheumatol       Date:  1987 Jan-Mar       Impact factor: 4.473

Review 8.  Correlation of functional properties of human lymphoid cell subsets and surface marker phenotypes using multiparameter analysis and flow cytometry.

Authors:  L L Lanier; E G Engleman; P Gatenby; G F Babcock; N L Warner; L A Herzenberg
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

9.  Lymphocytes recognize human vascular endothelial and dermal fibroblast Ia antigens induced by recombinant immune interferon.

Authors:  J S Pober; T Collins; M A Gimbrone; R S Cotran; J D Gitlin; W Fiers; C Clayberger; A M Krensky; S J Burakoff; C S Reiss
Journal:  Nature       Date:  1983 Oct 20-26       Impact factor: 49.962

10.  Monocyte-induced inhibition of lymphocyte response to phytohaemagglutinin in progressive systemic sclerosis.

Authors:  M D Lockshin; J A Markenson; L Fuzesi; S Kazanjian-Aram; C Joachim; M Ordene
Journal:  Ann Rheum Dis       Date:  1983-02       Impact factor: 19.103

View more
  10 in total

1.  Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation.

Authors:  G Valentini; A Baroni; K Esposito; C Naclerio; E Buommino; A Farzati; G Cuomo; B Farzati
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

2.  A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

Authors:  Arnold E Postlethwaite; Weng Kee Wong; Philip Clements; Soumya Chatterjee; Barri J Fessler; Andrew H Kang; Joseph Korn; Maureen Mayes; Peter A Merkel; Jerry A Molitor; Larry Moreland; Naomi Rothfield; Robert W Simms; Edwin A Smith; Robert Spiera; Virginia Steen; Kenneth Warrington; Barbara White; Frederick Wigley; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06

3.  Targeting STAT4 in systemic sclerosis: a promising new direction.

Authors:  Jammie Barnes; Sandeep K Agarwal
Journal:  Expert Rev Clin Immunol       Date:  2011-07       Impact factor: 4.473

4.  Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles.

Authors:  L D Carbone; K J Warrington; K D Barrow; M Pugazhenthi; M A Watsky; G Somes; J Ingels; A E Postlethwaite
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

5.  Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.

Authors:  Koichi Yanaba; Ayumi Yoshizaki; Yoshihide Asano; Takafumi Kadono; Shinichi Sato
Journal:  Clin Rheumatol       Date:  2011-01-19       Impact factor: 2.980

6.  Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines.

Authors:  Pravitt Gourh; Sandeep K Agarwal; Dipal Divecha; Shervin Assassi; Gene Paz; Rajpreet K Arora-Singh; John D Reveille; Sanjay Shete; Maureen D Mayes; Frank C Arnett; Filemon K Tan
Journal:  Arthritis Rheum       Date:  2009-12

7.  Basal Activation of Type I Interferons (Alpha2 and Beta) and 2'5'OAS Genes: Insights into Differential Expression Profiles of Interferon System Components in Systemic Sclerosis.

Authors:  Danilo Bretas de Oliveira; Gabriel Magno de Freitas Almeida; Antônio Carlos Martins Guedes; Flávia Patrícia Sena Teixeira Santos; Claudio Antônio Bonjardim; Paulo César Peregrino Ferreira; Erna Geessien Kroon
Journal:  Int J Rheumatol       Date:  2011-11-01

8.  Characterisation of the immune response to type I collagen in scleroderma.

Authors:  Kenneth J Warrington; Usha Nair; Laura D Carbone; Andrew H Kang; Arnold E Postlethwaite
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

9.  Determination of T Cell Responses in Thai Systemic Sclerosis Patients.

Authors:  Oranit Likhit; Worawit Louthrenoo; Sa-Nga Pattanakitsakul; Aroonroong Suttitheptumrong; Supot Hannongbua; Thanyada Rungrotmongkol; Hiroshi Noguchi; Fujio Takeuchi; Kobporn Boonnak
Journal:  J Immunol Res       Date:  2022-03-07       Impact factor: 4.818

10.  Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations.

Authors:  Pravitt Gourh; Frank C Arnett; Shervin Assassi; Filemon K Tan; Mei Huang; Laura Diekman; Maureen D Mayes; John D Reveille; Sandeep K Agarwal
Journal:  Arthritis Res Ther       Date:  2009-10-02       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.